Meeting
2023 ASCO Genitourinary Cancers Symposium
STARLITE 2: Phase 2 study of nivolumab plus 177lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC).
Authors
Darren R. Feldman
Memorial Sloan Kettering Cancer Center, New York, NY
Darren R. Feldman , Robert J. Motzer , Andrea Knezevic , Chung-Han Lee , Martin H Voss , Serge K. Lyashchenko , Hijin Park , Steven M. Larson , Neeta Pandit-Taskar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05239533
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr TPS752)
DOI
10.1200/JCO.2023.41.6_suppl.TPS752
Abstract #
TPS752
Poster Bd #
N10
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Results of a feasibility study of I-124 girentuximab in metastatic clear cell renal cell carcinoma (m ccRCC).
First Author: Stephen Michael Keefe
Poster
2023 ASCO Annual Meeting
Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC).
First Author: Katy Beckermann
Poster
2023 ASCO Genitourinary Cancers Symposium
Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A).
First Author: Michael B. Atkins
Poster
2022 ASCO Annual Meeting
A phase II study to evaluate the safety and efficacy of IMM-101 in combination with checkpoint inhibitors in patients with advanced melanoma: Final results of the IMM-101-015 trial.
First Author: Alberto Fusi